Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
Br J Haematol. 2020 Nov;191(4):521-526. doi: 10.1111/bjh.17149.
Over the past 60 years, haematologists and scientists from the United Kingdom, notably John Goldman and Tessa Holyoake, have punched above their weight in changing chronic myeloid leukaemia (CML) from an incurable and invariably fatal disease for all, to a chronic condition where over 90% have normal life expectancy. As a result, it is now difficult to power a worthwhile phase 3 study for newly diagnosed patients. Nevertheless, important clinical questions remain.
在过去的 60 年里，来自英国的血液学家和科学家们，尤其是 John Goldman 和 Tessa Holyoake，在改变慢性髓性白血病（CML）方面取得了巨大的成就。他们使这种曾经无法治愈、所有人都会致命的疾病，变成了一种慢性病，超过 90%的患者都能拥有正常的预期寿命。因此，现在为新诊断的患者进行有意义的 3 期研究变得非常困难。然而，仍然存在重要的临床问题。
